Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mona S. Elshahed, Dalia Mohamed, Tamer Nasr, Nageh Aboutaleb & Ola Zakaria. (2018) A Comparative Study of Smart Spectrophotometric Methods and a Densitometric Method for Simultaneous Determination of Binary Mixture of Canagliflozin and Metformin Hydrochloride. Analytical Chemistry Letters 8:1, pages 63-75.
Read now
Read now
André J. Scheen. (2017) Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 503-515.
Read now
Read now
Jingbo Hu, Ping Zou, Shuo Zhang, Minzhi Zhou & Xueying Tan. (2016) Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 17:18, pages 2471-2477.
Read now
Read now
Stewart B. Harris. (2016) The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Review of Clinical Pharmacology 9:11, pages 1453-1462.
Read now
Read now
Ronnie Aronson. (2015) Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Current Medical Research and Opinion 31:5, pages 901-911.
Read now
Read now
Articles from other publishers (20)
Eman A. Bahgat, Hisham Hashem, Hanaa Saleh, Ebraam B. Kamel & Maya S. Eissa. (2023) HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application. BMC Chemistry 17:1.
Crossref
Crossref
Georgia Noble-Bell & Comfort Bright-Davies. (2022) Safe use of sodium glucose co-transporter 2 inhibitors in the management of type 2 diabetes. Nursing Standard 38:1, pages 61-66.
Crossref
Crossref
Jonali Ramani, Harshil Shah, Vivek K. Vyas & Manmohan Sharma. (2022) A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports 6, pages 100074.
Crossref
Crossref
Noha S. Abbas, Yahya Abduh Salim Mohamed, Sayed M. Derayea, Mahmoud A. Omar & Gamal A. Saleh. (2021) Simple TLC–spectrodensitometric method for studying lipophilicity and quantitative analysis of hypoglycemic drugs in their binary mixture. Biomedical Chromatography 35:11.
Crossref
Crossref
Bjad K. Almutairy, El-Sayed Khafagy, Ahmed Alalaiwe, Mohammed F. Aldawsari, Saad M. Alshahrani, Bader B. Alsulays, Abdullah S. Alshetaili, Sultan M. Alshehri & Mohamed H. Fayed. (2020) Enhancing the Poor Flow and Tableting Problems of High Drug-Loading Formulation of Canagliflozin Using Continuous Green Granulation Process and Design-of-Experiment Approach. Pharmaceuticals 13:12, pages 473.
Crossref
Crossref
Anirudh Manoj, Subham Das, Anu Kunnath Ramachandran, Angel T Alex & Alex Joseph. (2020) SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. Future Medicinal Chemistry 12:21, pages 1961-1990.
Crossref
Crossref
Pranav A. Pandya, Priyanka A. Shah & Pranav S. Shrivastav. (2020) Separation of achiral anti-diabetic drugs using sub/supercritical fluid chromatography with a polysaccharide stationary phase: Thermodynamic considerations and molecular docking study. Journal of Pharmaceutical and Biomedical Analysis 189, pages 113452.
Crossref
Crossref
Dalia Mohamed, Mona S. Elshahed, Tamer Nasr, Nageh Aboutaleb & Ola Zakaria. (2019) Novel LC–MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. BMC Chemistry 13:1.
Crossref
Crossref
Priyanka A. Shah, Pranav S. Shrivastav, Vinay Sharma & Manish S. Yadav. (2019) Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 175, pages 112790.
Crossref
Crossref
Claudia Cosentino, Ilaria Dicembrini, Besmir Nreu, Edoardo Mannucci & Matteo Monami. (2019) Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice 155, pages 107808.
Crossref
Crossref
Florian Karl Zeugswetter, Theresa Polsterer, Herbert Krempl & Ilse Schwendenwein. (2018) Basal glucosuria in cats. Journal of Animal Physiology and Animal Nutrition 103:1, pages 324-330.
Crossref
Crossref
Firas Younis, Jonathan Leor, Zaid Abassi, Natalie Landa, Lea Rath, Kenneth Hollander, Nili Naftali-Shani & Talma Rosenthal. (2018) Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat. Journal of Cardiovascular Pharmacology and Therapeutics 23:4, pages 358-371.
Crossref
Crossref
Hayam M. Lotfy, Dalia Mohamed & Mona S. Elshahed. (2018) Different mathematical processing of absorption, ratio and derivative spectra for quantification of mixtures containing minor component: An application to the analysis of the recently co-formulated antidiabetic drugs; canagliflozin and metformin. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 189, pages 100-109.
Crossref
Crossref
Funda Datli Yakaryılmaz & Zeynel Abidin Öztürk. (2017) Treatment of type 2 diabetes mellitus in the elderly. World Journal of Diabetes 8:6, pages 278.
Crossref
Crossref
Francesc Formiga, Leocadio Rodr?guez-Ma?as & Ricardo G?mez-Huelgas. (2016) Papel de los inhibidores SGLT2 en el paciente anciano con diabetes mellitus; debemos evitar la discriminaci?n por raz?n de edad. Revista Espa?ola de Geriatr?a y Gerontolog?a 51:6, pages 307-308.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K.-C. Liu, Sarah J. Fink & Christopher J. O’Donnell. (2016) Synthetic approaches to the 2014 new drugs. Bioorganic & Medicinal Chemistry 24:9, pages 1937-1980.
Crossref
Crossref
Timothy J. Church & Stuart T. Haines. (2016) Treatment Approach to Patients With Severe Insulin Resistance. Clinical Diabetes 34:2, pages 97-104.
Crossref
Crossref
Qi Yan, Ning Ding & Yingxia Li. (2016) Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors. Carbohydrate Research 421, pages 1-8.
Crossref
Crossref
I. Dardi, T. Kouvatsos & S.A. Jabbour. (2016) SGLT2 inhibitors. Biochemical Pharmacology 101, pages 27-39.
Crossref
Crossref
Rachel M. Saroka, Michael P. Kane, Robert S. Busch, Jay. Watsky & Robert A. Hamilton. (2015) SGLT-2 Inhibitor Therapy Added to GLP-1 Agonist Therapy in the Management of T2DM. Endocrine Practice 21:12, pages 1315-1322.
Crossref
Crossref